Haemoptysis—coughing up blood from the lungs or airways—can range from a minor sign of irritation to a life-threatening medical emergency requiring urgent intervention. Understanding when and how to treat this symptom effectively is crucial, because the approach depends heavily on the amount of blood lost, the underlying cause, and the patient’s overall health.

Understanding Treatment Priorities in Haemoptysis

When someone begins coughing up blood, the main goal of treatment is not always immediately clear to patients or even general practitioners. The priority shifts depending on how much blood appears and how quickly the situation deteriorates. Treatment aims to achieve three fundamental goals: stopping the bleeding as quickly as possible, preventing blood from entering the lungs and blocking the airways (a process called aspiration), and identifying and treating whatever underlying disease is causing the bleeding in the first place.^[10] In many cases, particularly when the amount of blood is small, the bleeding stops on its own without any specific intervention beyond treating the infection or condition that triggered it.^[1]

The severity of haemoptysis dictates the treatment approach. Mild haemoptysis—less than about 20 milliliters, or roughly a tablespoon of blood—often resolves without major medical intervention.^[2] More than 90 percent of mild cases stop bleeding without needing aggressive procedures, and patients typically recover well with basic supportive care and treatment of the cause.^[12] However, massive or life-threatening haemoptysis, which involves coughing up large volumes of blood (generally more than 100 to 600 milliliters in 24 hours, depending on expert definitions), is a completely different scenario.^[2][15] In these cases, death is not usually caused by losing too much blood, but rather by the blood blocking the airways and preventing oxygen from reaching the lungs—a condition known as asphyxiation.^[14][15]

Treatment depends greatly on what is causing the bleeding. Infections like bronchitis, pneumonia, and tuberculosis are among the most common triggers worldwide, particularly in regions where tuberculosis remains widespread.^[7][12] Other important causes include lung cancer, damaged airways from conditions like bronchiectasis (permanent widening of the airways), chronic obstructive pulmonary disease, blood clots in the lungs, and various inflammatory diseases.^[2][4] Sometimes, despite thorough investigation, doctors cannot identify any specific cause, a situation that occurs in about 20 to 50 percent of cases.^[12][17]

Standard Treatment Approaches

Standard treatment for haemoptysis varies widely depending on the severity and the underlying condition. When the bleeding is mild and self-limiting, doctors often focus on treating the cause rather than the bleeding itself. For instance, if a bacterial respiratory infection like bronchitis or pneumonia is identified, antibiotics are prescribed to eliminate the infection, which in turn stops the bleeding.^[1][7] Common bacterial infections respond to standard antibiotics targeting organisms such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.^[12] Treatment duration typically spans 5 to 14 days depending on the specific infection and patient response.

When tuberculosis is the culprit—particularly common in certain geographic regions—patients receive a combination of anti-tuberculosis medications for an extended period, often six to nine months.^[7] This regimen usually includes drugs such as isoniazid, rifampicin, pyrazinamide, and ethambutol in specific combinations prescribed by guidelines from medical societies. Stopping tuberculosis treatment prematurely can lead to recurrent haemoptysis and drug resistance, so adherence to the full course is critical.

In cases where bleeding is more significant but not immediately life-threatening, supportive medical measures become important. Patients may receive oxygen therapy to maintain adequate oxygen levels in the blood, especially if breathing is compromised.^[10] Positioning the patient is also crucial—if doctors know which lung is bleeding, they position the patient with the bleeding side down to prevent blood from flowing into the healthy lung and causing further problems.^[10][15] Medications that suppress coughing, called antitussives, may be used cautiously in some situations to reduce the force of coughing and minimize further bleeding, although this approach is debated because coughing also helps clear blood from the airways.^[16]

In massive haemoptysis, emergency measures take precedence. Securing the airway is the first and most critical step. This may involve inserting a breathing tube into the windpipe (intubation) to keep airways open and deliver oxygen effectively.^[15] In some cases, doctors use specialized double-lumen breathing tubes that allow them to isolate the bleeding lung from the healthy one, preventing blood from spreading and ensuring that at least one lung can function properly. This procedure is complex and requires expertise in intensive care settings.

Blood transfusions may be necessary if significant blood loss has occurred, though this is less common than airway management since asphyxiation is the primary danger rather than blood loss itself.^[14] Doctors also review any medications the patient is taking that could worsen bleeding, such as blood thinners like warfarin or aspirin, and may temporarily stop or reverse these drugs.^[5][11]

Side effects of standard treatments vary. Antibiotics can cause nausea, diarrhea, allergic reactions, and in some cases, disruption of the normal bacterial balance in the body. Anti-tuberculosis drugs have more serious potential side effects, including liver damage, vision changes, and nerve problems, which require careful monitoring during treatment. Intubation and mechanical ventilation, while life-saving, carry risks such as lung injury, infection, and complications from prolonged use.

Advanced Procedures for Controlling Bleeding

When medications and supportive care are insufficient to stop the bleeding, doctors turn to more invasive procedures. Three main approaches are used depending on the situation: bronchoscopy (examining and treating the airways with a camera), bronchial artery embolization (blocking the blood vessels supplying blood to the lungs), and surgery.

Bronchoscopy

Bronchoscopy involves inserting a thin, flexible tube with a camera and light into the airways through the mouth or nose to directly visualize where the bleeding is coming from.^[6][10] This procedure serves both diagnostic and therapeutic purposes. It helps doctors locate the exact site of bleeding and identify the underlying cause, such as a tumor, foreign object, or damaged tissue. Once the bleeding site is found, doctors can use various techniques through the bronchoscope to stop the bleeding directly.

Several methods can be applied during therapeutic bronchoscopy. Doctors may apply cold saline solution to constrict blood vessels, use medications that promote clotting directly at the bleeding site, or apply mechanical pressure with a balloon catheter to compress the bleeding vessel.^[15][16] More advanced techniques include using lasers or electrocoagulation to seal off bleeding vessels with heat.^[10] In some cases, doctors inject substances like epinephrine or apply topical thrombin to promote local clotting.

While flexible bronchoscopy is most commonly used because it can be performed at the bedside in intensive care units, rigid bronchoscopy is sometimes preferred in massive haemoptysis.^[15] The rigid scope has a larger diameter, allowing better clearing of blood from the airways and providing better visibility. It also enables the use of larger instruments for more aggressive treatment. However, rigid bronchoscopy requires general anesthesia and is typically performed in an operating room.

Bronchoscopy carries some risks, including bleeding (ironically), infection, collapsed lung, and reactions to sedation or anesthesia.^[6] Most patients tolerate the procedure well, though throat soreness and temporary breathing difficulties may occur afterward. The success of bronchoscopic treatment varies depending on the cause of bleeding and the specific technique used, but it provides immediate access to the problem and can be life-saving in emergencies.

Bronchial Artery Embolization

Bronchial artery embolization has become the first-line treatment for massive haemoptysis that originates from the high-pressure bronchial circulation, which accounts for about 90 percent of cases.^[10][15] The bronchial arteries, which branch from the main aorta to supply blood to the airways, operate at much higher pressure than the pulmonary arteries that supply the lung tissue. When these vessels are damaged by disease, they can bleed profusely.

The procedure involves an interventional radiologist threading a thin catheter through a blood vessel in the groin or arm and guiding it to the bronchial arteries using X-ray imaging.^[8][10] Once the bleeding vessel is identified through contrast dye injection, the radiologist injects small particles or coils through the catheter to block the artery and stop blood flow to the bleeding site. Common materials used for embolization include polyvinyl alcohol particles, gelatin sponge, or metallic coils.^[15]

Bronchial artery embolization achieves immediate control of bleeding in 75 to 98 percent of cases, making it highly effective.^[10][12] The procedure is less invasive than surgery and can be performed relatively quickly, often within hours of identifying the need. However, the recurrence rate of bleeding after embolization can be significant—ranging from 10 to 55 percent depending on the underlying disease—because the procedure addresses the bleeding vessel but not necessarily the underlying condition causing it.^[15] Patients with chronic conditions like bronchiectasis or tuberculosis may experience repeated bleeding episodes requiring multiple embolization procedures.

Complications of bronchial artery embolization include chest pain (the most common), fever, difficulty swallowing, and, rarely, serious complications like spinal cord injury if particles inadvertently travel to arteries supplying the spinal cord.^[10][15] The anatomy of bronchial arteries varies significantly among individuals, and identifying all the arteries that might be contributing to bleeding can be challenging. Some patients have abnormal or additional bronchial arteries that arise from unusual locations, which the radiologist must identify and treat to achieve complete bleeding control.^[15]

Surgery

Surgical removal of diseased lung tissue is reserved for specific situations when other treatments fail or are not suitable. Surgery is most appropriate when bleeding continues despite embolization, when there is a localized area of damaged lung tissue that can be safely removed, or when the underlying condition requires surgical treatment (such as certain lung cancers or traumatic injuries).^[10][13]

The extent of surgery depends on how much lung tissue is affected. Procedures range from removing a small wedge of lung tissue to removing an entire lobe (lobectomy) or even an entire lung (pneumonectomy).^[5] The decision depends on the location and extent of disease and the patient’s overall lung function. Removing too much lung tissue can leave the patient with inadequate breathing capacity, so careful assessment before surgery is essential.

Surgery carries significant risks, particularly in patients who are actively bleeding or have compromised lung function from underlying disease. Risks include infection, prolonged air leaks from the lung, breathing difficulties, blood clots, and complications from anesthesia.^[10] Recovery from lung surgery typically takes several weeks to months, and patients may experience ongoing breathing limitations depending on how much lung tissue was removed. Despite these risks, surgery can be curative for localized disease and provides definitive treatment when other approaches fail. The mortality rate from surgery for massive haemoptysis ranges from 10 to 40 percent, reflecting the serious nature of the condition and the compromised state of many patients requiring this intervention.^[15]

Treatment in Clinical Trials

Research into new treatments for haemoptysis focuses primarily on improving existing techniques rather than testing entirely new drugs, as haemoptysis is a symptom rather than a disease itself. Clinical trials in this area tend to evaluate innovative approaches to bronchoscopic treatment, refinements in embolization techniques, and better ways to identify bleeding sources quickly.

One area of active investigation involves newer bronchoscopic technologies. Researchers are studying the effectiveness of endobronchial ultrasound and other advanced imaging modalities that can be used during bronchoscopy to better identify bleeding sources and guide treatment more precisely. These techniques are being evaluated in Phase II and Phase III studies comparing them to standard bronchoscopy in terms of successful bleeding localization and treatment outcomes.

Another focus involves improving embolization materials and techniques. Clinical trials are examining different types of embolic agents—the materials used to block blood vessels—to determine which provide the best combination of immediate bleeding control and lowest recurrence rates. Some studies are investigating the use of newer liquid embolic agents that can penetrate smaller vessels more effectively than traditional particles, potentially improving long-term outcomes. These trials typically occur in specialized centers with interventional radiology expertise and enroll patients experiencing moderate to massive haemoptysis who have failed medical management.

Researchers are also studying combinations of treatments to improve outcomes. For example, some trials investigate whether performing bronchial artery embolization before surgery in patients with massive haemoptysis improves surgical outcomes by reducing blood loss during the operation and stabilizing the patient beforehand. These Phase III studies compare patients who receive combination treatment to those who undergo surgery alone, measuring outcomes such as surgical complications, blood transfusion requirements, and mortality rates.

In patients with recurrent haemoptysis from chronic conditions like bronchiectasis, clinical trials are evaluating preventive strategies. These include long-term antibiotic regimens (inhaled or oral) aimed at reducing airway inflammation and infection that trigger bleeding episodes, antifibrinolytic agents like tranexamic acid that promote clotting, and anti-inflammatory medications. Phase II studies of tranexamic acid, for instance, have shown some promise in reducing bleeding frequency in patients with chronic haemoptysis, though larger Phase III trials are needed to confirm these findings and establish optimal dosing.

For patients with haemoptysis related to lung cancer, clinical trials often focus on how different cancer treatments affect bleeding risk and control. Studies examine whether newer targeted therapies or immunotherapies for lung cancer reduce bleeding complications compared to traditional chemotherapy, and whether certain drugs specifically designed to inhibit blood vessel formation in tumors (anti-angiogenic agents) can prevent haemoptysis. Some of these trials are conducted in major cancer centers across Europe, the United States, and other regions, enrolling patients with specific types of lung cancer who meet particular eligibility criteria related to their disease stage and overall health.

Eligibility for clinical trials evaluating haemoptysis treatments typically depends on the severity of bleeding, the underlying cause, previous treatments attempted, and overall patient health status. Many trials exclude patients with certain comorbidities or those who are too unstable for the experimental intervention being tested. Patients interested in participating in trials should discuss options with their pulmonologist or interventional radiologist, who can identify appropriate studies and facilitate enrollment if suitable.

Most common treatment methods

• Medical management
  • Antibiotic therapy for bacterial infections such as bronchitis, pneumonia, or tuberculosis, using agents targeting specific organisms
  • Oxygen supplementation to maintain adequate blood oxygen levels
  • Blood transfusions if significant blood loss occurs
  • Correction of bleeding disorders or reversal of anticoagulant medications
  • Cough suppressants used selectively to reduce bleeding triggered by forceful coughing
  • Patient positioning with the bleeding side down to protect the healthy lung
• Bronchoscopic interventions
  • Flexible or rigid bronchoscopy to visualize and locate the bleeding source
  • Application of iced saline lavage to constrict blood vessels and promote clotting
  • Topical application of vasoconstrictors like epinephrine directly to bleeding sites
  • Balloon tamponade to compress bleeding vessels mechanically
  • Laser photocoagulation or electrocoagulation to seal bleeding vessels with heat
  • Application of topical hemostatic agents such as thrombin or fibrin glue
• Bronchial artery embolization
  • Catheter-based procedure performed by interventional radiologists to block bleeding bronchial arteries
  • Use of embolic materials including polyvinyl alcohol particles, gelatin sponge, or metallic coils
  • Identification of abnormal or accessory bronchial arteries using contrast angiography
  • Achieves immediate bleeding control in 75 to 98 percent of cases
  • Can be repeated if bleeding recurs
• Surgical treatment
  • Lung resection ranging from wedge resection to lobectomy or pneumonectomy
  • Reserved for cases where medical and interventional treatments fail
  • Appropriate for localized disease such as specific lung cancers, aspergillomas, or bronchiectasis
  • Used in traumatic or iatrogenic vascular injuries requiring urgent repair
  • Video-assisted thoracic surgery or open thoracotomy depending on the situation
• Airway management in massive haemoptysis
  • Endotracheal intubation to secure the airway and prevent asphyxiation
  • Use of double-lumen tubes to isolate the bleeding lung from the healthy lung
  • Mechanical ventilation to support breathing during acute bleeding episodes
  • Intensive care monitoring of vital signs and oxygen levels